IceCure Medical (ICCM) Q4 2025 Earnings Transcript

NodeGuardian

2026-03-23 06:43:20

Abstract generation in progress

IceCure Medical reported record Q4 and full-year 2025 revenues, driven by the U.S. FDA marketing authorization of its ProSense cryoablation system for low-risk early-stage breast cancer. The company is expanding its U.S. commercial team and customer base, while also advancing regulatory submissions in Canada and Japan, supported by new medical guidelines recommending cryoablation for select patients. Management anticipates significant growth, especially after securing a CPT1 code in early 2028, which will further establish ProSense as a standard of care.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.